USA - NYSE:NVS - US66987V1098 - ADR
Overall NVS gets a fundamental rating of 7 out of 10. We evaluated NVS against 195 industry peers in the Pharmaceuticals industry. NVS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. NVS is valued quite cheap, while showing a decent growth score. This is a good combination! Finally NVS also has an excellent dividend rating. This makes NVS very considerable for value and dividend and quality investing!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 13.08% | ||
ROE | 32.52% | ||
ROIC | 22.91% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 33.45% | ||
PM (TTM) | 24.9% | ||
GM | 76.12% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.57 | ||
Debt/FCF | 1.93 | ||
Altman-Z | 4.04 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.82 | ||
Quick Ratio | 0.62 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 14.85 | ||
Fwd PE | 13.76 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 15.14 | ||
EV/EBITDA | 11.5 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.35% |
131.43
+0.66 (+0.5%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.35% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 14.85 | ||
Fwd PE | 13.76 | ||
P/S | 4.64 | ||
P/FCF | 15.14 | ||
P/OCF | 12.24 | ||
P/B | 6.06 | ||
P/tB | N/A | ||
EV/EBITDA | 11.5 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 13.08% | ||
ROE | 32.52% | ||
ROCE | 25.24% | ||
ROIC | 22.91% | ||
ROICexc | 25.24% | ||
ROICexgc | 149.23% | ||
OM | 33.45% | ||
PM (TTM) | 24.9% | ||
GM | 76.12% | ||
FCFM | 30.64% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.57 | ||
Debt/FCF | 1.93 | ||
Debt/EBITDA | 0.99 | ||
Cap/Depr | 66.33% | ||
Cap/Sales | 7.26% | ||
Interest Coverage | 19.66 | ||
Cash Conversion | 85.38% | ||
Profit Quality | 123.09% | ||
Current Ratio | 0.82 | ||
Quick Ratio | 0.62 | ||
Altman-Z | 4.04 |